LY3532226 + dulaglutide

**LY3532226 + dulaglutide** is an investigational combination therapy comprised of LY3532226, a novel agent under development, and dulaglutide, a well-established glucagon-like peptide 1 receptor agonist (GLP-1 RA) indicated for type 2 diabetes and marketed under the brand name Trulicity. Dulaglutide works by binding the GLP-1 receptor, enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, thereby improving glycemic control. LY3532226 is in clinical trials for type 2 diabetes and obesity, but its precise mechanism of action is not publicly disclosed. The combination is being evaluated for its safety, tolerability, and efficacy in patients with type 2 diabetes and obesity[1][6][7].

Other names

dulaglutide